论文部分内容阅读
目的:探讨2型糖尿病患者采取利拉鲁肽治疗的有效性与安全性。方法:随机将120例2型糖尿病患者均分为2组,各60例,对照组采取格列美脲治疗,研究组采取利拉鲁肽治疗。观察记录两组治疗前后糖化血红蛋白(Hb A1c)、空腹血糖(FPG)、餐后2h血糖(2h PPG)变化,以及不良反应情况,并对比分析。结果:两组患者治疗后FPG、2h PPG、Hb A1c均有明显改善(P<0.05),但研究组改善更显著(P<0.05);研究组不良反应发生率显著低于对照组(P<0.05)。结论:2型糖尿病患者采取利拉鲁肽治疗可取得不错的效果,可明显改善血糖水平,而且安全性很高,值得借鉴。
Objective: To investigate the efficacy and safety of liraglutide in type 2 diabetic patients. Methods: 120 cases of type 2 diabetes were randomly divided into two groups, 60 cases each. The control group was treated with glimepiride, and the study group was treated with liraglutide. The changes of Hb A1c, fasting blood glucose (FPG), postprandial 2h blood glucose (2h PPG) and adverse reactions in both groups were observed and compared before and after treatment. Results: The FPG, 2h PPG and Hb A1c in both groups were significantly improved (P <0.05), but the improvement in the study group was more significant (P <0.05). The incidence of adverse reactions in the study group was significantly lower than that in the control group (P < 0.05). Conclusion: The treatment of type 2 diabetes patients with liraglutide can achieve good results, can significantly improve blood glucose levels, and high safety, it is worth learning.